Stock Track | Liquidia Technologies Soars 5% in Pre-Market on Strong Q4 Results, Revenue Beat and Return to Profitability

Stock Track03-05

Liquidia Technologies Inc's stock surged 5.00% in pre-market trading following the release of its fourth quarter and full year 2025 financial results.

The company reported a significant swing to profitability in the fourth quarter, with net income of $14.6 million compared to a loss of $38.5 million in the same period last year. Revenue for the quarter reached $92.02 million, surpassing analyst consensus estimates of $87.49 million. This marks the company's second consecutive quarter of profitability since launching its YUTREPIA product.

Liquidia's CEO, Dr. Roger Jeffs, highlighted the strong commercial performance of YUTREPIA, which achieved net product sales of $148.3 million for the full year 2025, with $90.1 million coming in the fourth quarter alone. The company reported more than 3,600 unique prescriptions and over 2,900 patients treated since the product's launch in June 2025, indicating robust market adoption and growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189821899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189821899","market":"nz","top_or_hot":-1,"title":"Stock Track | Liquidia Technologies Soars 5% in Pre-Market on Strong Q4 Results, Revenue Beat and Return to Profitability","media":"Stock Track","content":"<p>Liquidia Technologies Inc's stock surged 5.00% in pre-market trading following the release of its fourth quarter and full year 2025 financial results.</p><p>The company reported a significant swing to profitability in the fourth quarter, with net income of $14.6 million compared to a loss of $38.5 million in the same period last year. Revenue for the quarter reached $92.02 million, surpassing analyst consensus estimates of $87.49 million. This marks the company's second consecutive quarter of profitability since launching its YUTREPIA product.</p><p>Liquidia's CEO, Dr. Roger Jeffs, highlighted the strong commercial performance of YUTREPIA, which achieved net product sales of $148.3 million for the full year 2025, with $90.1 million coming in the fourth quarter alone. The company reported more than 3,600 unique prescriptions and over 2,900 patients treated since the product's launch in June 2025, indicating robust market adoption and growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Liquidia Technologies Soars 5% in Pre-Market on Strong Q4 Results, Revenue Beat and Return to Profitability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Liquidia Technologies Soars 5% in Pre-Market on Strong Q4 Results, Revenue Beat and Return to Profitability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-05 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Liquidia Technologies Inc's stock surged 5.00% in pre-market trading following the release of its fourth quarter and full year 2025 financial results.</p><p>The company reported a significant swing to profitability in the fourth quarter, with net income of $14.6 million compared to a loss of $38.5 million in the same period last year. Revenue for the quarter reached $92.02 million, surpassing analyst consensus estimates of $87.49 million. This marks the company's second consecutive quarter of profitability since launching its YUTREPIA product.</p><p>Liquidia's CEO, Dr. Roger Jeffs, highlighted the strong commercial performance of YUTREPIA, which achieved net product sales of $148.3 million for the full year 2025, with $90.1 million coming in the fourth quarter alone. The company reported more than 3,600 unique prescriptions and over 2,900 patients treated since the product's launch in June 2025, indicating robust market adoption and growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"","article_id":"1189821899","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189821899","pubTimestamp":1772712162,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Liquidia Technologies Inc's stock surged 5.00% in pre-market trading following the release of its fourth quarter and full year 2025 financial results.The company reported a significant swing to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc"},"translate_title":"个股追踪|Liquidia Technologies盘前大涨5%，Q4业绩强劲，营收超预期并恢复盈利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"Liquidia Technologies Inc's stock surged 5.00% in pre-market trading following the release of its fourth quarter and full year 2025 financial results.The company reported a significant swing to profitability in the fourth quarter, with net income of $14.6 million compared to a loss of $38.5 million in the same period last year. Revenue for the quarter reached $92.02 million, surpassing analyst consensus estimates of $87.49 million. This marks the company's second consecutive quarter of profitability since launching its YUTREPIA product.Liquidia's CEO, Dr. Roger Jeffs, highlighted the strong commercial performance of YUTREPIA, which achieved net product sales of $148.3 million for the full year 2025, with $90.1 million coming in the fourth quarter alone. The company reported more than 3,600 unique prescriptions and over 2,900 patients treated since the product's launch in June 2025, indicating robust market adoption and growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189821899","isCrawlerRequest":true}